Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study

Inclusion Criteria: * Histologically diagnosed non-Hodgkin's lymphoma patients treated by CHOP-regimen or R (Rituximab)-CHOP regimen at 21±5 days interval * Age \>= 20 years old * The patients with at least one of the following risk factor of neutropenic fever at initiation of anti-cancer treatment 1. Age \>= 65 years old 2. Progressed stage of disease (Ann Arbor stage III) 3. History of previous anti-cancer treatment 4. History of previous radiotherapy (Including bone region includes bone marrow) 5. Bone marrow involvement 6. Comorbid neutropenia (neutrophils \< 1,500/uL ) before the initiation of anti-cancer treatment 7. Comorbid anemia (hemoglobin \< 12.0 g/dL ) before the initiation of anti-cancer treatment 8. Evidence of activated inflammation 9. Existence of open wound 10. Poor health state (ECOG 2) 11. Poor nutritional state (Serum albumin \< 3.5 g/dL) 12. Kidney disease or renal insufficiency 13. Liver disease (chronic hepatitis or cirrhosis) or hepatic insufficiency 14. Chronic Obstructive Pulmonary Disease (COPD) 15. Cardiovascular disease 16. Diabetes mellitus * Increased cardiac output by 50% above the baseline without clinically significant abnormal findings on MUGA or echocardiography * life expectancy \>=6 months * Amenorrhea less than 1 year (less than 1 year after menopause) or premenopausal female with negative response to serum or urine pregnancy test before initiation of the treatment * Voluntary participants with written consent agreement for this study Exclusion Criteria: * The patients treated by other anti-cancer treatment except CHOP regimen or R (Rituximab)-CHOP regimen at 21 days interval * Pregnant or breast feeding woman, fertile woman without appropriate contraception * Patients with hypersensitivity against study drugs * Patients treated by other study medication or co-treatment with anticancer chemotherapy, hormone therapy, and immunotherapy